COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

Lancet

Volumn 360, Issue 9339, 2002, Pages 1071-1073

  Ray, Wayne A ^a,b   Stein, C Michael ^a   Daugherty, James R ^a   Hall, Kathi ^a   Arbogast, Patrick G ^a   Griffin, Marie R ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGED; ARTICLE; COMMUNITY; CONTROLLED STUDY; CORONARY RISK; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0037027050     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11131-7     Document Type: Article

References (5)

1. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528.
2. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286:2001;954-959.
3. Ray W.A., Stein C.M., Hall K., Daugherty J.R., Griffin M.R. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet. 359:2002;118-123.
4. Solomon D.H., Glynn R.J., Levin R., Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 162:2002;1099-1104.
5. Food and Drug Administration. Medical Officer review, 1999: Vioxx. NDA 21-042. http://www.fda.gov/cder/foi/nda/99/021042_52_vioxx.htm (accessed July 31, 2002).